# EDGAR Filing Document

**Accession Number:** 0001503274
**File Stem:** 0002120516-26-000008
**Filing Date:** 2026-5
**Character Count:** 11538
**Document Hash:** ad582b52a7e7616422c3dd215e4fb9c9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0002120516-26-000008.hdr.sgml**: 20260518

**ACCESSION NUMBER**: 0002120516-26-000008

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260515

**FILED AS OF DATE**: 20260518

**DATE AS OF CHANGE**: 20260518

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Miller Michael Francis
- **CENTRAL INDEX KEY:** 0002120516

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38319
- **FILM NUMBER:** 26995121

**MAIL ADDRESS:**
- **STREET 1:** C/O QUANTERIX CORPORATION
- **STREET 2:** 900 MIDDLESEX TURNPIKE
- **CITY:** BILLERICA
- **STATE:** MA
- **ZIP:** 02181
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Quanterix Corp
- **CENTRAL INDEX KEY:** 0001503274
- **STANDARD INDUSTRIAL CLASSIFICATION:** LABORATORY ANALYTICAL INSTRUMENTS [3826]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 208957988
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 900 MIDDLESEX TURNPIKE
- **CITY:** BILLERICA
- **STATE:** MA
- **ZIP:** 01821
- **BUSINESS PHONE:** 617-301-9400

**MAIL ADDRESS:**
- **STREET 1:** 900 MIDDLESEX TURNPIKE
- **CITY:** BILLERICA
- **STATE:** MA
- **ZIP:** 01821

## Ex-24

```

POWER OF ATTORNEY

Know all by these presents that the undersigned hereby constitutes
and appoints each of Daniel Char, Michael Lanieri, Bonnie McManus, and
Meghan Shevlin as the undersigned's true and lawful attorney-in-fact
to:

execute for and on behalf of the undersigned, in the undersigned's
capacity as a beneficial owner of Quanterix Corporation (the
"Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of
the Securities Exchange Act of 1934 and the rules thereunder and
Schedules 13D and 13G in accordance with Section 13 of the
Securities Exchange Act of 1934 and the rules thereunder;

do and perform any and all acts for and on behalf of the undersigned
which may be necessary or desirable to complete and execute any
such Form 3, 4, or 5 or Schedules 13D or 13G, complete and execute
any amendment or amendments thereto, and timely file such form with
the U.S. Securities and Exchange Commission (the "SEC") and any
securities exchange or similar authority; and

take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of
benefit to, in the best interest of, or legally required by, the
undersigned, it being understood that the documents executed by
such attorney-in-fact on behalf of the undersigned pursuant to this
Power of Attorney shall be in such form and shall contain such
terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.

The undersigned hereby grants to each attorney-in-fact full power
and authority to do and perform any and every act and thing
whatsoever requisite, necessary, or proper to be done in the
exercise of any of the rights and powers herein granted, as fully
to all intents and purposes as the undersigned might or could do
if personally present, with full power of substitution or
revocation, hereby ratifying and confirming all that such
attorney-in-fact, or such attorney-in-fact's substitute or
substitutes, shall lawfully do or cause to be done by virtue of
this power of attorney and the rights and powers herein granted.
The undersigned also ratifies hereby any action previously taken
by each attorney-in-fact that would have been authorized by this
power of attorney if it had been in effect at the time such action
was taken. The undersigned acknowledges that each foregoing
attorney-in-fact, in serving in such capacity at the request of
the undersigned, is not assuming, nor is the Company assuming,
any of the undersigned's responsibilities to comply with
Sections 13 and 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect
until the undersigned is no longer required to file Forms 3, 4,
and 5 and Schedules 13D and 13G with respect to the undersigned's
holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing
delivered to each foregoing attorney-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney
to be executed as of this 17th day of February 2026.

/s/ Michael F. Miller name: Michael Miller

```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Miller Michael Francis<br><sub>(Last) (First) (Middle)</sub><br>C/O QUANTERIX CORPORATION<br>900 MIDDLESEX TURNPIKE<br><sub>(Street)</sub><br>BILLERICA, MA 01821<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-05-15 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Chief Technology Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Quanterix Corp [ QTRX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2026-05-15 |  | M |  | 81.00 | A | <sup>(1)</sup> | 32694.00 | D |  |
| Common Stock | 2026-05-15 |  | F |  | 25.00 | D | $2.75 | 32669.00 | D |  |
| Common Stock | 2026-05-15 |  | M |  | 136.00 | A | <sup>(1)</sup> | 32805.00 | D |  |
| Common Stock | 2026-05-15 |  | F |  | 41.00 | D | $2.75 | 32764.00 | D |  |
| Common Stock | 2026-05-15 |  | M |  | 135.00 | A | <sup>(1)</sup> | 32899.00 | D |  |
| Common Stock | 2026-05-15 |  | F |  | 41.00 | D | $2.75 | 32858.00 | D |  |
| Common Stock | 2026-05-15 |  | M |  | 372.00 | A | <sup>(1)</sup> | 33230.00 | D |  |
| Common Stock | 2026-05-15 |  | F |  | 111.00 | D | $2.75 | 33119.00 | D |  |
| Common Stock | 2026-05-15 |  | M |  | 834.00 | A | <sup>(1)</sup> | 33953.00 | D |  |
| Common Stock | 2026-05-15 |  | F |  | 249.00 | D | $2.75 | 33704.00 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Restricted Stock Unit | $0.00 | 2026-05-15 |  | M |  |  | 81.00 | <sup>(2)</sup> | <sup>(2)</sup> | Common Stock | 81.00 | $0.00 | 760.00 | D |  |
| Restricted Stock Unit | $0.00 | 2026-05-15 |  | M |  |  | 136.00 | <sup>(3)</sup> | <sup>(3)</sup> | Common Stock | 136.00 | $0.00 | 1389.00 | D |  |
| Restricted Stock Unit | $0.00 | 2026-05-15 |  | M |  |  | 135.00 | <sup>(4)</sup> | <sup>(4)</sup> | Common Stock | 135.00 | $0.00 | 2846.00 | D |  |
| Restricted Stock Unit | $0.00 | 2026-05-15 |  | M |  |  | 372.00 | <sup>(5)</sup> | <sup>(5)</sup> | Common Stock | 372.00 | $0.00 | 8945.00 | D |  |
| Restricted Stock Unit | $0.00 | 2026-05-15 |  | M |  |  | 834.00 | <sup>(6)</sup> | <sup>(6)</sup> | Common Stock | 834.00 | $0.00 | 27525.00 | D |  |

---

### Footnotes:

(1) Restricted stock units convert into common stock on a one-for-one basis.

(2) On February 6, 2023, the reporting person was granted 3,929 restricted stock units, vesting 25% on the first anniversary of the grant date, with the remaining 75% vesting in 36 equal monthly installments on the 15th day of each month thereafter.

(3) On March 15, 2023, the reporting person was granted 6,566 restricted stock units, vesting 25% on the first anniversary of the grant date, with the remaining 75% vesting in 36 equal monthly installments on the 15th day of each month thereafter.

(4) On February 2, 2024, the reporting person was granted 6,494 restricted stock units, vesting 25% on the first anniversary of the grant date, with the remaining 75% vesting in 36 equal monthly installments on the 15th day of each month thereafter.

(5) On May 21, 2024, the reporting person was granted 17,878 restricted stock units, vesting 25% on the first anniversary of the grant date, with the remaining 75% vesting in 36 equal monthly installments on the 15th day of each month thereafter.

(6) On February 4, 2025, the reporting person was granted 40,036 restricted stock units, vesting 25% on the first anniversary of the grant date, with the remaining 75% vesting in 36 equal monthly installments on the 15th day of each month thereafter.

**Signature:** /s/ Bonnie McManus, Attorney-in-Fact  
**Date:** 2026-05-18

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**